Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $3.7 million.

  • Ligand Pharmaceuticals' Accounts Payables fell 2162.33% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 2162.33%. This contributed to the annual value of $5.2 million for FY2024, which is 11561.6% up from last year.
  • Ligand Pharmaceuticals' Accounts Payables amounted to $3.7 million in Q3 2025, which was down 2162.33% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Accounts Payables registered a high of $19.2 million during Q2 2022, and its lowest value of $1.8 million during Q2 2024.
  • Moreover, its 5-year median value for Accounts Payables was $6.1 million (2023), whereas its average is $7.5 million.
  • In the last 5 years, Ligand Pharmaceuticals' Accounts Payables tumbled by 8442.12% in 2023 and then surged by 37875.07% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Accounts Payables stood at $8.4 million in 2021, then tumbled by 36.84% to $5.3 million in 2022, then tumbled by 54.27% to $2.4 million in 2023, then surged by 115.62% to $5.2 million in 2024, then dropped by 29.7% to $3.7 million in 2025.
  • Its last three reported values are $3.7 million in Q3 2025, $8.6 million for Q2 2025, and $5.4 million during Q1 2025.